Nuvelo (Nasdaq: NUVO) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nuvelo (Nasdaq: NUVO)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dr Goodhybe who wrote (28)	2/21/1999 3:45:00 PM
From: John Starks	Read Replies (1) of 286

Just wondering if you had any other thoughts on HYSQ since this post.I am also skeptical about its claims of having "10 million partial gene sequences, making it the largest [partial gene] database in the world." Since you seem to be in the field, have you heard any thing recently about HYSQ and its legal problems with AFFX? My interest in HYSQ stems more from their CD39 holdings. They announced this month that they are trying to develop a CD39-based (ectoapyrase) thrombosis therapy, as they acquired rights to development from Imperial Cancer Research this month. They must have pulled out a soluble isoform in one of their screens. CD39 is a potent inhibitor of platelet aggregation and recruitment to wounds. I am familiar with the animal data on sCD39 (published in J of Clin Invest. 1998) and it is promising, in terms of solubility, activity in vitro, in vivo half-life and non-toxicity (all in mice). Although this is all pre-clinical data, interest in CD39 has been keen and the market for such a product is obviously huge, so I'm keeping my eye out for phase I data.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next